All Stories

  1. Habitual exercisers versus sedentary subjects with Parkinson's Disease: Multimodal PET and fMRI study

    Article • Movement Disorders, October 2018, Wiley

    A Jon Stoessl

  2. Win-Concurrent Sensory Cues Can Promote Riskier Choice

    Article • Journal of Neuroscience, October 2018, Society for Neuroscience

    A Jon Stoessl

  3. Operationalizing Neuroimaging for Disorders of Consciousness in the Canadian Context

    Article • Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, September 2018, Cambridge University Press

    A Jon Stoessl

  4. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country Delphi-panel approach

    Article • Current Medical Research and Opinion, August 2018, Taylor & Francis

    Leah Kleinman, A Jon Stoessl

  5. Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going

    Article • Movement Disorders, August 2018, Wiley

    A Jon Stoessl, GAETANO Barbagallo

  6. PBB3 binding in a patient with corticobasal syndrome

    Article • Movement Disorders, June 2018, Wiley

    A Jon Stoessl

  7. Conclusions

    Article • Movement Disorders, May 2018, Wiley

    A Jon Stoessl

  8. Dyskinesias and levodopa therapy: why wait?

    Article • Journal of Neural Transmission, February 2018, Springer Science + Business Media

    A Jon Stoessl

  9. Challenges and unfulfilled promises in Parkinson's disease

    Article • The Lancet Neurology, November 2017, Elsevier

    A Jon Stoessl

  10. DNAJC12 and dopa-responsive nonprogressive parkinsonism

    Article • Annals of Neurology, October 2017, Wiley

    A Jon Stoessl

  11. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy

    Article • Movement Disorders, September 2017, Wiley

    Dr Maria Stamelou, Dr Andres Lozano, Hagai Bergman, A Jon Stoessl, Dr Mayela Rodríguez-Violante

  12. Homozygous alpha-synuclein p.A53V in familial Parkinson's disease

    Article • Neurobiology of Aging, September 2017, Elsevier

    A Jon Stoessl

  13. PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins

    Article • Movement Disorders, June 2017, Wiley

    A Jon Stoessl

  14. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies

    Article • The Lancet Neurology, May 2017, Elsevier

    A Jon Stoessl

  15. Gender differences in Parkinson's disease depression

    Article • Parkinsonism & Related Disorders, March 2017, Elsevier

    A Jon Stoessl

  16. Glucose utilization: still in the synapse

    Article • Nature Neuroscience, March 2017, Springer Science + Business Media

    A Jon Stoessl

  17. The underlying mechanism of prodromal PD: insights from the parasympathetic nervous system and the olfactory system

    Article • Translational Neurodegeneration, February 2017, Springer Science + Business Media

    A Jon Stoessl

  18. Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers

    Article • Movement Disorders, February 2017, Wiley

    A Jon Stoessl

  19. Editors' Note: The 200th Anniversary of the Shaking Palsy

    Article • Movement Disorders, January 2017, Wiley

    A Jon Stoessl

  20. Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient

    Article • Annals of Neurology, January 2017, Wiley

    A Jon Stoessl

  21. Tau imaging in progressive supranuclear palsy

    Article • Movement Disorders, November 2016, Wiley

    A Jon Stoessl

  22. Renovo

    Article • Journal of Parkinson s Disease, October 2016, IOS Press

    Zuzanna Kurowska, A Jon Stoessl

  23. Ethical and Clinical Considerations at the Intersection of Functional Neuroimaging and Disorders of Consciousness

    Article • Cambridge Quarterly of Healthcare Ethics, September 2016, Cambridge University Press

    A Jon Stoessl

  24. Reply to letter to the editor: Is there anything more to learn from SWEDD?

    Article • Movement Disorders, August 2016, Wiley

    A Jon Stoessl

  25. DCTN1 p.K56R in progressive supranuclear palsy

    Article • Parkinsonism & Related Disorders, July 2016, Elsevier

    A Jon Stoessl

  26. Raul de la Fuente-Fernandez, February 22, 1959-May 11, 2016

    Article • Movement Disorders, June 2016, Wiley

    A Jon Stoessl

  27. Salivary gland biopsy for diagnosis of Parkinson's disease?

    Article • The Lancet Neurology, June 2016, Elsevier

    A Jon Stoessl

  28. The role of biomarkers and imaging in Parkinson’s disease

    Article • Expert Review of Neurotherapeutics, February 2016, Taylor & Francis

    A Jon Stoessl

  29. Movement disorders

    Article • January 2016, Elsevier

    A Jon Stoessl

  30. Optimizing diagnosis in Parkinson's disease: Radionuclide imaging

    Article • Parkinsonism & Related Disorders, January 2016, Elsevier

    A Jon Stoessl

  31. Comment: Increased D3binding—A substrate for levodopa-induced dyskinesias?

    Article • Neurology, December 2015, Wolters Kluwer Health

    A Jon Stoessl

  32. A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier

    Article • Movement Disorders, December 2015, Wiley

    A Jon Stoessl

  33. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease

    Article • Progress in Neurobiology, September 2015, Elsevier

    A Jon Stoessl

  34. Canadian Perspectives on the Clinical Actionability of Neuroimaging in Disorders of Consciousness

    Article • Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, March 2015, Cambridge University Press

    A Jon Stoessl

  35. The Saskatchewan Movement Disorders Program: Commitment Pays Off

    Article • Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, February 2015, Cambridge University Press

    A Jon Stoessl

  36. Imaging in Parkinson’s disease: time to look below the neck

    Article • Brain, February 2015, Oxford University Press (OUP)

    A Jon Stoessl

  37. Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity

    Article • Acta Neuropathologica Communications, January 2015, Springer Science + Business Media

    A Jon Stoessl

  38. Clinical Correlations With Lewy Body Pathology in LRRK2 -Related Parkinson Disease

    Article • JAMA Neurology, January 2015, American Medical Association (AMA)

    A Jon Stoessl

  39. DNAJC13genetic variants in parkinsonism

    Article • Movement Disorders, November 2014, Wiley

    Professor Carles Vilarino-Guell, A Jon Stoessl

  40. A familial form of parkinsonism, dementia, and motor neuron disease: A longitudinal study

    Article • Parkinsonism & Related Disorders, November 2014, Elsevier

    A Jon Stoessl

  41. Central pharmacokinetics of levodopa: Lessons from imaging studies

    Article • Movement Disorders, October 2014, Wiley

    A Jon Stoessl

  42. Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism

    Article • Movement Disorders, September 2014, Wiley

    Professor Carles Vilarino-Guell, A Jon Stoessl

  43. DAT-SPECT diagnoses dopamine depletion, but not PD

    Article • Movement Disorders, August 2014, Wiley

    A Jon Stoessl

  44. Imaging insights into basal ganglia function, Parkinson's disease, and dystonia

    Article • The Lancet, August 2014, Elsevier

    A Jon Stoessl

  45. In vivo dopaminergic and serotonergic dysfunction inDCTN1gene mutation carriers

    Article • Movement Disorders, May 2014, Wiley

    A Jon Stoessl

  46. Gene therapy for Parkinson's disease: a step closer?

    Article • The Lancet, March 2014, Elsevier

    A Jon Stoessl

  47. Developments in neuroimaging: positron emission tomography

    Article • Parkinsonism & Related Disorders, January 2014, Elsevier

    A Jon Stoessl

  48. Imaging of Dopamine and Serotonin Receptors and Transporters

    Article • January 2014, Elsevier

    A Jon Stoessl

  49. Insights into LRRK2-Mutation Related PD from PET Imaging Studies

    Article • January 2014, Elsevier

    A Jon Stoessl

  50. Parkinson’s Disease

    Article • January 2014, Springer Science + Business Media

    A Jon Stoessl

  51. The effects of exercise on cognition in Parkinson’s disease: a systematic review

    Article • Translational Neurodegeneration, January 2014, Springer Science + Business Media

    A Jon Stoessl

  52. Measurements of Dopaminergic Function in the Rat Brain Using [18F]FDOPA PET and Microdialysis

    Article • January 2014, Elsevier

    A Jon Stoessl

  53. Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions

    Article • Pharmacology & Therapeutics, December 2013, Elsevier

    A Jon Stoessl

  54. DNAJC13 mutations in Parkinson disease

    Article • Human Molecular Genetics, November 2013, Oxford University Press (OUP)

    Professor Carles Vilarino-Guell, A Jon Stoessl

  55. Decisions under risk in Parkinson’s disease: Preserved evaluation of probability and magnitude

    Article • Neuropsychologia, November 2013, Elsevier

    A Jon Stoessl

  56. SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia

    Article • Neurogenetics, October 2013, Springer Science + Business Media

    A Jon Stoessl

  57. The Nature of Progression in Parkinson’s Disease: An Application of Non-Linear, Multivariate, Longitudinal Random Effects Modelling

    Article • PLoS ONE, October 2013, PLOS

    A Jon Stoessl

  58. Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations

    Article • Parkinsonism & Related Disorders, October 2013, Elsevier

    A Jon Stoessl

  59. Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers

    Article • Neurology, September 2013, Wolters Kluwer Health

    A Jon Stoessl

  60. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease

    Article • Movement Disorders, March 2013, Wiley

    Professor Carles Vilarino-Guell, A Jon Stoessl

  61. Novel spatial analysis method for PET images using 3D moment invariants: Applications to Parkinson's disease

    Article • NeuroImage, March 2013, Elsevier

    A Jon Stoessl

  62. Neurology in Canada: History of the Canadian Neurological Society

    Article • Neurology, January 2013, Wolters Kluwer Health

    A Jon Stoessl

  63. Measuring dopaminergic function in the 6-OHDA-lesioned rat: a comparison of PET and microdialysis

    Article • EJNMMI Research, January 2013, Springer Science + Business Media

    A Jon Stoessl

  64. Neuroimaging of Sleep and Sleep Disorders

    Article • January 2013, Cambridge University Press

    A Jon Stoessl

  65. Imaging striatal dopaminergic function inPhospholipase A2 Group VI-related parkinsonism

    Article • Movement Disorders, November 2012, Wiley

    A Jon Stoessl

  66. In-vivo Measurement of LDOPA Uptake, Dopamine Reserve and Turnover in the Rat Brain Using [18F]FDOPA PET

    Article • Journal of Cerebral Blood Flow & Metabolism, August 2012, SAGE Publications

    A Jon Stoessl

  67. Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research

    Article • PLoS ONE, August 2012, PLOS

    A Jon Stoessl

  68. Biomarkers for trials of neuroprotection in Parkinson's disease

    Article • Movement Disorders, August 2012, Wiley

    A Jon Stoessl

  69. Imaging neural correlates of mild cognitive impairment in Parkinson's disease

    Article • The Lancet Neurology, August 2012, Elsevier

    A Jon Stoessl

  70. Neuroimaging: Current role in detecting pre-motor Parkinson's disease

    Article • Movement Disorders, April 2012, Wiley

    A Jon Stoessl

  71. DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function

    Article • Neurobiology of Aging, April 2012, Elsevier

    A Jon Stoessl

  72. Variant ataxia-telangiectasia presenting as primary-appearing dystonia in Canadian Mennonites

    Article • Neurology, February 2012, Wolters Kluwer Health

    A Jon Stoessl, MD Michael S Okun

  73. Neuroimaging

    Article • January 2012, Elsevier

    A Jon Stoessl

  74. Neuroimaging in the early diagnosis of neurodegenerative disease

    Article • Translational Neurodegeneration, January 2012, Springer Science + Business Media

    A Jon Stoessl

  75. Cerebrospinal fluid amyloid   and tau in LRRK2 mutation carriers

    Article • Neurology, December 2011, Wolters Kluwer Health

    A Jon Stoessl

  76. Advances in imaging in Parkinson's disease

    Article • The Lancet Neurology, November 2011, Elsevier

    A Jon Stoessl

  77. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease

    Article • Brain, November 2011, Oxford University Press (OUP)

    A Jon Stoessl

  78. Liquid Xenon Detectors for Positron Emission Tomography

    Article • Journal of Physics Conference Series, September 2011, Institute of Physics Publishing

    A Jon Stoessl

  79. Dopaminergic Imaging in Parkinson’s Disease: PET

    Article • September 2011, Oxford University Press (OUP)

    A Jon Stoessl

  80. Functional Imaging Studies in Parkinson's Disease: The Non-Dopaminergic Systems

    Article • June 2011, Wiley

    A Jon Stoessl

  81. A family with parkinsonism, essential tremor, restless legs syndrome, and depression

    Article • Neurology, May 2011, Wolters Kluwer Health

    Professor Carles Vilarino-Guell, A Jon Stoessl

  82. Milestones in neuroimaging

    Article • Movement Disorders, May 2011, Wiley

    A Jon Stoessl

  83. Ethical Issues In The Management Of Parkinson’S Disease

    Article • April 2011, Oxford University Press (OUP)

    A Jon Stoessl

  84. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease

    Article • Annals of Neurology, January 2011, Wiley

    A Jon Stoessl

  85. Neuroimaging in Parkinson’s Disease

    Article • Neurotherapeutics, January 2011, Springer Science + Business Media

    A Jon Stoessl

  86. Movement disorders: new insights into Parkinson's disease

    Article • The Lancet Neurology, January 2011, Elsevier

    A Jon Stoessl

  87. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers

    Article • Movement Disorders, October 2010, Wiley

    A Jon Stoessl

  88. Parkin and Parkinson's disease: Differentiated by non-dopaminergic dysfunction?

    Article • Experimental Neurology, September 2010, Elsevier

    A Jon Stoessl

  89. Effects of Expectation on Placebo-Induced Dopamine Release in Parkinson Disease

    Article • Archives of General Psychiatry, August 2010, American Medical Association (AMA)

    A Jon Stoessl

  90. Continuous dopaminergic therapy in Parkinson disease: Time to stride back?

    Article • Annals of Neurology, June 2010, Wiley

    A Jon Stoessl

  91. Response to Heat Pain Stimulation in Idiopathic Parkinson's Disease

    Article • Pain Medicine, June 2010, Oxford University Press (OUP)

    A Jon Stoessl

  92. Effect of electroconvulsive therapy on brain 5-HT2 receptors in major depression

    Article • The British Journal of Psychiatry, May 2010, Royal College of Psychiatrists

    Dr Raymond W Lam, A Jon Stoessl

  93. Scans without evidence of dopamine deficiency: The triumph of careful clinical assessment

    Article • Movement Disorders, April 2010, Wiley

    A Jon Stoessl

  94. Dopamine transporter PET in normal aging: Dopamine transporter decline and its possible role in preservation of motor function

    Article • Synapse, February 2010, Wiley

    A Jon Stoessl

  95. Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications

    Article • January 2010, Elsevier

    A Jon Stoessl

  96. Functional imaging studies of non-motoric manifestations of Parkinson's Disease

    Article • Parkinsonism & Related Disorders, December 2009, Elsevier

    A Jon Stoessl

  97. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study

    Article • Brain, August 2009, Oxford University Press (OUP)

    A Jon Stoessl

  98. Genetic factors influencing age at onset in LRRK2-linked Parkinson disease

    Article • Parkinsonism & Related Disorders, August 2009, Elsevier

    Dr Ronald F Pfeiffer, A Jon Stoessl

  99. Visualizing vesicular dopamine dynamics in Parkinson's disease

    Article • Synapse, August 2009, Wiley

    A Jon Stoessl

  100. Familial parkinsonism: Study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes

    Article • Parkinsonism & Related Disorders, May 2009, Elsevier

    A Jon Stoessl

  101. Pallidonigral TDP-43 pathology in Perry syndrome

    Article • Parkinsonism & Related Disorders, May 2009, Elsevier

    A Jon Stoessl

  102. Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson’s: anin vivoimaging study

    Article • Journal of Neurochemistry, April 2009, Wiley

    A Jon Stoessl

  103. DCTN1 mutations in Perry syndrome

    Article • Nature Genetics, January 2009, Springer Science + Business Media

    Professor Carles Vilarino-Guell, A Jon Stoessl

  104. Radionuclide scanning to diagnose Parkinson disease: is it cost-effective?

    Article • Nature Clinical Practice Neurology, December 2008, Springer Science + Business Media

    A Jon Stoessl

  105. Progression of dopaminergic dysfunction in a LRRK2 kindred: A multitracer PET study

    Article • Neurology, November 2008, Wolters Kluwer Health

    A Jon Stoessl

  106. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias

    Article • Neurology, November 2008, Wolters Kluwer Health

    A Jon Stoessl

  107. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: A double blind video-based analysis

    Article • Movement Disorders, November 2008, Wiley

    A Jon Stoessl

  108. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

    Article • The Lancet Neurology, May 2008, Elsevier

    A Jon Stoessl

  109. Invited Article: Functional imaging in Parkinson disease

    Article • Neurology, April 2008, Wolters Kluwer Health

    A Jon Stoessl

  110. Potential therapeutic targets for Parkinson's disease

    Article • Expert Opinion on Therapeutic Targets, March 2008, Informa Healthcare

    A Jon Stoessl

  111. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease

    Article • Annals of Neurology, March 2008, Wiley

    A Jon Stoessl

  112. Neuroimaging

    Article • January 2008, Elsevier

    A Jon Stoessl

  113. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa

    Article • Movement Disorders, September 2007, Wiley

    A Jon Stoessl

  114. Gene therapy for Parkinson's disease: early data

    Article • The Lancet, June 2007, Elsevier

    A Jon Stoessl

  115. Understanding the Placebo Effect: Contributions from Neuroimaging

    Article • Molecular Imaging and Biology, March 2007, Springer Science + Business Media

    A Jon Stoessl

  116. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study

    Article • Annals of Neurology, January 2007, Wiley

    A Jon Stoessl

  117. Is there seasonal variation in risk of Parkinson's disease?

    Article • Movement Disorders, January 2007, Wiley

    A Jon Stoessl

  118. Positron emission tomography in premotor Parkinson's disease

    Article • Parkinsonism & Related Disorders, January 2007, Elsevier

    A Jon Stoessl

  119. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease

    Article • Movement Disorders, January 2007, Wiley

    A Jon Stoessl

  120. Correction

    Article • Annals of Neurology, December 2006, Wiley

    A Jon Stoessl

  121. Autosomal dominant dystonia-plus with cerebral calcifications

    Article • Neurology, August 2006, Wolters Kluwer Health

    A Jon Stoessl

  122. Genetic heterogeneity in paroxysmal nonkinesigenic dyskinesia

    Article • Neurology, May 2006, Wolters Kluwer Health

    A Jon Stoessl

  123. Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: Positron emission tomographic studies

    Article • Movement Disorders, March 2006, Wiley

    A Jon Stoessl

  124. GDNF in treatment of Parkinson's disease: response to editorial

    Article • The Lancet Neurology, March 2006, Elsevier

    A Jon Stoessl

  125. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

    Article • Annals of Neurology, March 2006, Wiley

    A Jon Stoessl

  126. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications

    Article • Brain, February 2006, Oxford University Press (OUP)

    A Jon Stoessl

  127. Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation

    Article • Movement Disorders, January 2006, Wiley

    A Jon Stoessl

  128. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation

    Article • Brain, August 2005, Oxford University Press (OUP)

    A Jon Stoessl

  129. Positron emission tomography after fetal transplantation in Huntington's disease

    Article • Annals of Neurology, July 2005, Wiley

    A Jon Stoessl

  130. Treatment for the progression of Parkinson's disease

    Article • The Lancet Neurology, April 2005, Elsevier

    A Jon Stoessl

  131. Parkinson's disease: in vivo assessment of disease progression using positron emission tomography

    Article • Molecular Brain Research, March 2005, Elsevier

    A Jon Stoessl

  132. The placebo response as a reward mechanism

    Article • Seminars in Pain Medicine, March 2005, Elsevier

    A Jon Stoessl

  133. Hot spots: Can positron emission tomography offer insights into the pathogenesis of PD?

    Article • Annals of Neurology, January 2005, Wiley

    A Jon Stoessl

  134. Positron Emission Tomography in Parkinson’s Disease

    Article • December 2004, Taylor & Francis

    A Jon Stoessl

  135. The Placebo Effect in Parkinson’s Disease

    Article • December 2004, Taylor & Francis

    A Jon Stoessl

  136. Lack of Regional Selectivity During the Progression of Parkinson Disease

    Article • Archives of Neurology, December 2004, American Medical Association (AMA)

    A Jon Stoessl

  137. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias

    Article • Brain, November 2004, Oxford University Press (OUP)

    A Jon Stoessl

  138. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology

    Article • Neuron, November 2004, Elsevier

    Dr Ronald F Pfeiffer, A Jon Stoessl

  139. Tremor induced by thalamic deep brain stimulation in patients with complex regional facial pain

    Article • Movement Disorders, August 2004, Wiley

    A Jon Stoessl

  140. Clustering of Parkinson Disease

    Article • Archives of Neurology, July 2004, American Medical Association (AMA)

    A Jon Stoessl

  141. Placebo mechanisms and reward circuitry: clues from Parkinson's disease

    Article • Biological Psychiatry, July 2004, Elsevier

    A Jon Stoessl

  142. Willing oneself better on placebo—effective in its own right

    Article • The Lancet, July 2004, Elsevier

    A Jon Stoessl

  143. Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2)

    Article • Movement Disorders, June 2004, Wiley

    A Jon Stoessl

  144. Presynaptic mechanisms of motor fluctuations in Parkinson’s disease: a probabilistic model

    Article • Brain, April 2004, Oxford University Press (OUP)

    A Jon Stoessl

  145. Impact of the Spatial Normalization Template and Realignment Procedure on the SPM Analysis of [11C]Raclopride PET Studies

    Article • IEEE Transactions on Nuclear Science, February 2004, Institute of Electrical & Electronics Engineers (IEEE)

    A Jon Stoessl

  146. The PARK8 Locus in Autosomal Dominant Parkinsonism: Confirmation of Linkage and Further Delineation of the Disease-Containing Interval

    Article • The American Journal of Human Genetics, January 2004, Elsevier

    Dr Ronald F Pfeiffer, A Jon Stoessl

  147. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease

    Article • Experimental Neurology, November 2003, Elsevier

    A Jon Stoessl

  148. [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease

    Article • Brain, September 2003, Oxford University Press (OUP)

    A Jon Stoessl

  149. Agonizing over dopaminergic replacement therapy—lessons from animal models of parkinson’s disease

    Article • Experimental Neurology, September 2003, Elsevier

    A Jon Stoessl

  150. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

    Article • Annals of Neurology, August 2003, Wiley

    A Jon Stoessl

  151. Neural transplantation for the treatment of Parkinson's disease

    Article • The Lancet Neurology, July 2003, Elsevier

    A Jon Stoessl

  152. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

    Article • Annals of Neurology, June 2003, Wiley

    A Jon Stoessl

  153. Central administration of the neurotensin receptor antagonist sr48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia

    Article • Neuroscience, June 2003, Elsevier

    A Jon Stoessl

  154. VMAT2 binding is elevated in dopa-responsive dystonia: Visualizing empty vesicles by PET

    Article • Synapse, April 2003, Wiley

    A Jon Stoessl

  155. Leg muscle strength is reduced in Parkinson's disease and relates to the ability to rise from a chair

    Article • Movement Disorders, January 2003, Wiley

    A Jon Stoessl

  156. Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa

    Article • Neuroscience, January 2003, Elsevier

    A Jon Stoessl

  157. The Biochemical Bases for Reward

    Article • Evaluation & the Health Professions, December 2002, SAGE Publications

    A Jon Stoessl

  158. Age and severity of nigrostriatal damage at onset of Parkinson's disease

    Article • Synapse, November 2002, Wiley

    A Jon Stoessl

  159. SCA-2 presenting as parkinsonism in an Alberta family: Clinical, genetic, and PET findings

    Article • Neurology, November 2002, Wolters Kluwer Health

    A Jon Stoessl

  160. Dopamine release in human ventral striatum and expectation of reward

    Article • Behavioural Brain Research, November 2002, Elsevier

    A Jon Stoessl

  161. Rett Syndrome: Investigation of Nine Patients, including PET Scan

    Article • Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, November 2002, Cambridge University Press

    A Jon Stoessl

  162. PET Study of the Effects of Valproate on Dopamine D 2 Receptors in Neuroleptic- and Mood-Stabilizer-Naive Patients With Nonpsychotic Mania

    Article • American Journal of Psychiatry, October 2002, American Psychiatric Association

    Dr Raymond W Lam, A Jon Stoessl

  163. Parkinsonʼs disease: imaging update

    Article • Current Opinion in Neurology, August 2002, Wolters Kluwer Health

    A Jon Stoessl

  164. “Stiff in the Closet” - Who Provides Care for Parkinsonian Patients?

    Article • Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, August 2002, Cambridge University Press

    A Jon Stoessl

  165. [18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism

    Article • Movement Disorders, July 2002, Wiley

    Dr Pramod Kr Pal, A Jon Stoessl

  166. Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia

    Article • Neuroscience, July 2002, Elsevier

    A Jon Stoessl

  167. Somatostatin modulates the behavioral effects of dopamine receptor activation in parkinsonian rats

    Article • Neuroscience, June 2002, Elsevier

    A Jon Stoessl

  168. The placebo effect in Parkinson's disease

    Article • Trends in Neurosciences, June 2002, Elsevier

    A Jon Stoessl

  169. The placebo effect in neurological disorders

    Article • The Lancet Neurology, June 2002, Elsevier

    A Jon Stoessl

  170. PET Study of [ 18 F]6-Fluoro- l -Dopa Uptake in Neuroleptic- and Mood-Stabilizer-Naive First-Episode Nonpsychotic Mania: Effects of Treatment With Divalproex Sodium

    Article • American Journal of Psychiatry, May 2002, American Psychiatric Association

    Dr Raymond W Lam, A Jon Stoessl

  171. Bilateral human fetal striatal transplantation in Huntington's disease

    Article • Neurology, March 2002, Wolters Kluwer Health

    A Jon Stoessl

  172. Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson's disease and correlates with PET [18F]-DOPA Ki

    Article • Parkinsonism & Related Disorders, October 2001, Elsevier

    A Jon Stoessl

  173. Daytime somnolence in patients with Parkinson's disease

    Article • Parkinsonism & Related Disorders, October 2001, Elsevier

    A Jon Stoessl

  174. Assessing the integrity of the dopamine system in Parkinson's disease: How best to do it?

    Article • Movement Disorders, September 2001, Wiley

    A Jon Stoessl

  175. Positron emission tomography of dopamine pathways in familial Parkinsonian syndromes

    Article • Parkinsonism & Related Disorders, September 2001, Elsevier

    A Jon Stoessl

  176. Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease

    Article • Science, August 2001, American Association for the Advancement of Science

    A Jon Stoessl

  177. Antisense strategies for the treatment of neurological disease

    Article • Expert Opinion on Therapeutic Patents, April 2001, Informa Healthcare

    A Jon Stoessl

  178. Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal dementia with parkinsonism linked to chromosome 17 and point mutation in tau gene)

    Article • Parkinsonism & Related Disorders, April 2001, Elsevier

    A Jon Stoessl

  179. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover

    Article • Annals of Neurology, March 2001, Wiley

    A Jon Stoessl

  180. Pharmacodynamic modeling of oral levodopa in Parkinson's disease

    Article • Annals of Neurology, January 2001, Wiley

    A Jon Stoessl

  181. Dopamine D1A receptor function in a rodent model of tardive dyskinesia

    Article • Neuroscience, November 2000, Elsevier

    A Jon Stoessl

  182. Effects of oligonucleotide antisense to dopamine D1A receptor messenger RNA in a rodent model of levodopa-induced dyskinesia

    Article • Neuroscience, June 2000, Elsevier

    A Jon Stoessl

  183. Unilateral pallidotomy for reduction of parkinsonian pain

    Article • Journal of Neurosurgery, August 1999, Journal of Neurosurgery Publishing Group (JNSPG)

    A Jon Stoessl

  184. Neuroreceptor imaging: new developments in PET and SPECT imaging of neuroreceptor binding (including dopamine transporters, vesicle transporters and post synaptic receptor sites)

    Article • Current Opinion in Neurology, August 1998, Wolters Kluwer Health

    A Jon Stoessl

  185. Effect of age on caudate dopaminergic function in idiopathic Parkinsonism

    Article • Parkinsonism & Related Disorders, June 1998, Elsevier

    A Jon Stoessl

  186. Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa-responsive dystonia measured with [11C]-raclopride and positron-emission tomography

    Article • Neurology, April 1998, Wolters Kluwer Health

    A Jon Stoessl

  187. The effects of CCK-4 on dopamine D1 agonist-induced grooming are blocked by a CCKA receptor antagonist: Evidence for a novel CCK receptor subtype?

    Article • Neuropharmacology, November 1997, Elsevier

    A Jon Stoessl

  188. Pallidotomy for tardive dyskinesia

    Article • The Lancet, March 1997, Elsevier

    A Jon Stoessl

  189. Effects of graft-derived dopaminergic innervation on the target neurons of patch and matrix compartments of the striatum

    Article • Neuroscience, January 1997, Elsevier

    A Jon Stoessl

  190. The Neurotensin Antagonist SR 48692 Fails to Modify the Behavioural Responses to a Dopamine D1 Receptor Agonist in the Rat

    Article • Neuropharmacology, January 1997, Elsevier

    A Jon Stoessl

  191. Which dopamine receptor(s) do we need for motor function? Lessons from gene targeting and translational blockade

    Article • Parkinsonism & Related Disorders, October 1996, Elsevier

    A Jon Stoessl

  192. Effects of ethanol in a putative rodent model of tardive dyskinesia

    Article • Pharmacology Biochemistry and Behavior, July 1996, Elsevier

    A Jon Stoessl

  193. Behavioural evidence for cholecystokinin-dopamine D1 receptor interactions in the rat

    Article • European Journal of Pharmacology, February 1996, Elsevier

    A Jon Stoessl

  194. Absence of Mutations in Superoxide Dismutase and Catalase Genes in Patients With Parkinson's Disease

    Article • Archives of Neurology, December 1995, American Medical Association (AMA)

    A Jon Stoessl

  195. Pharmacological characterization of grooming induced by a selective NK-1 tachykinin receptor agonist

    Article • Brain Research, November 1995, Elsevier

    A Jon Stoessl

  196. Environmental Exposures in Elderly Canadians With Parkinson’s Disease

    Article • Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, August 1995, Cambridge University Press

    A Jon Stoessl

  197. Effects of neurotensin in a rodent model of tardive dyskinesia

    Article • Neuropharmacology, April 1995, Elsevier

    A Jon Stoessl

  198. Dopamine D1 receptor agonist-induced grooming is blocked by the opioid receptor antagonist naloxone

    Article • European Journal of Pharmacology, July 1994, Elsevier

    A Jon Stoessl

  199. Localization of striatal and nigral tachykinin receptors in the rat

    Article • Brain Research, May 1994, Elsevier

    A Jon Stoessl

  200. Effects of ageing on tachykinin function in the basal ganglia

    Article • Brain Research, December 1993, Elsevier

    A Jon Stoessl

  201. Neuroleptic-induced chewing movements in the rat are suppressed by peripherally but not centrally administered CCK and abolished by bilateral subdiaphragmatic vagotomy

    Article • Neuropharmacology, June 1993, Elsevier

    A Jon Stoessl

  202. The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia

    Article • Movement Disorders, January 1993, Wiley

    A Jon Stoessl

  203. Behavioural effects of selective tachykinin agonists in midbrain dopamine regions

    Article • Brain Research, November 1991, Elsevier

    A Jon Stoessl

  204. Neurotensin and neurotensin analogues modify the effects of chronic neuroleptic administration in the rat

    Article • Brain Research, September 1991, Elsevier

    A Jon Stoessl

  205. Autoradiographic visualization of NK-3 tachykinin binding sites in the rat brain, utilizing [3H]senktide

    Article • Brain Research, November 1990, Elsevier

    A Jon Stoessl

  206. Pharmacological characterization of the behavioral syndrome induced by the NK-3 tachykinin agonist senktide in rodents: evidence for mediation by endogenous 5-HT

    Article • Brain Research, May 1990, Elsevier

    A Jon Stoessl, Dr Colin Dourish

  207. Effects of ageing on the behavioural responses to dopamine agonists: decreased yawning and locomotion, but increased stereotypy

    Article • Brain Research, August 1989, Elsevier

    A Jon Stoessl, Dr Colin Dourish

  208. Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists

    Article • Psychopharmacology, July 1989, Springer Science + Business Media

    A Jon Stoessl, Dr Colin Dourish

  209. The NK-3 tachykinin agonist senktide elicits yawning and chewing mouth movements following subcutaneous administration in the rat. Evidence for cholinergic mediation

    Article • Psychopharmacology, August 1988, Springer Science + Business Media

    A Jon Stoessl, Dr Colin Dourish

  210. The NK-3 tachykinin receptor agonist senktide elicits 5-HT-mediated behaviour following central or peripheral administration in mice and rats

    Article • British Journal of Pharmacology, June 1988, Wiley

    A Jon Stoessl, Dr Colin Dourish

  211. Apomorphine-induced yawning in rats is abolished by bilateral 6-hydroxydopamine lesions of the substantia nigra

    Article • Psychopharmacology, November 1987, Springer Science + Business Media

    A Jon Stoessl, Dr Colin Dourish

  212. Senktide, a selective neurokinin B-like agonist, elicits serotonin-mediated behaviour following intracisternal administration in the mouse

    Article • Neuroscience Letters, October 1987, Elsevier

    A Jon Stoessl, Dr Colin Dourish

  213. Controlling for Cerebral Atrophy in Positron Emission Tomography Data

    Article • Journal of Cerebral Blood Flow & Metabolism, August 1987, SAGE Publications

    A Jon Stoessl

  214. Regression Model for Predicting Dissociations of Regional Cerebral Glucose Metabolism in Individuals at Risk for Huntington's Disease

    Article • Journal of Cerebral Blood Flow & Metabolism, December 1986, SAGE Publications

    A Jon Stoessl

  215. Dementia in Movement Disorders

    Article • Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, November 1986, Cambridge University Press

    A Jon Stoessl

  216. DOUBLE-BLIND STUDY OF BOTULINUM TOXIN IN SPASMODIC TORTICOLLIS

    Article • The Lancet, August 1986, Elsevier

    A Jon Stoessl

  217. Glucose Use Correlations: A Matter of Inference

    Article • Journal of Cerebral Blood Flow & Metabolism, August 1986, SAGE Publications

    A Jon Stoessl

  218. Cerebral metabolism of glucose in benign hereditary chorea

    Article • Movement Disorders, January 1986, Wiley

    A Jon Stoessl

  219. (+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (PHNO), A NEW DOPAMINOMIMETIC, IN TREATMENT OF PARKINSONISM

    Article • The Lancet, December 1985, Elsevier

    A Jon Stoessl

  220. Nemaline Myopathy With Associated Cardiomyopathy

    Article • Archives of Neurology, November 1985, American Medical Association (AMA)

    A Jon Stoessl

  221. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease

    Article • Nature, September 1985, Springer Science + Business Media

    A Jon Stoessl

  222. Synthesis of thromboxane B2 and prostaglandins by bovine gastric mucosal microsomes

    Article • Prostaglandins, November 1977, Elsevier

    A Jon Stoessl

  223. Positron Emission Tomography in Parkinson’s Disease

    Article • Springer Science + Business Media

    A Jon Stoessl

  224. Neuroimaging of Parkinson's disease

    Article • Cambridge University Press

    A Jon Stoessl

  225. Imaging of the Parkinsonian Brain in Relation to Restorative Therapy

    Article • Springer Science + Business Media

    A Jon Stoessl

  226. Imaging of the Parkinsonian Brain in Relation to Restorative Therapy

    Article • Springer Science + Business Media

    A Jon Stoessl